NCT06600906 Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer Status RECRUITING Phase N/A
NCT06598007 A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors Status RECRUITING Phase PHASE1/PHASE2
NCT06592664 Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC Status WITHDRAWN Phase PHASE1/PHASE2
NCT06586515 MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors Status RECRUITING Phase PHASE1
NCT06574620 Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment Status RECRUITING Phase NA
NCT06562192 Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers Status RECRUITING Phase PHASE1
NCT06549725 Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening Status RECRUITING Phase NA
NCT06528093 A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy Status TERMINATED Phase PHASE1
NCT06503146 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection Status RECRUITING Phase PHASE2
NCT06492915 Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06478862 Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy Status TERMINATED Phase PHASE2
NCT06445062 Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors Status RECRUITING Phase PHASE1/PHASE2
NCT06428409 A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) Status RECRUITING Phase PHASE1/PHASE2
NCT06345599 PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study) Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT06344299 Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma Status COMPLETED Phase N/A
NCT06320717 AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma Status RECRUITING Phase N/A
NCT06305247 A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2